J1308
J1308 – Inj, famotidine, 0.25 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 16 NDCs crosswalked per 0.25 MG $0.008/unit ASP+6%
📋 J1308 summary
J1308 is a HCPCS Level II J-code used to bill famotidine, 0.25 mg, billed per 0.25 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Code J1308
Billing unit 0.25 MG Payment limit $0.008/unit NDC-Crosswalk 16
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ1308
DescriptorInj, famotidine, 0.25 mg
Billing unit0.25 MG
Payment limit / unit$0.008
Est. ASP / unit$0.008 est.
Mapped NDCs16
Data periodQ3 2026
Last updated2026-08-20
💊 About Famotidine DRUG GUIDE
Famotidine treats a range of acid-related conditions.
Over-the-counter tablet products — including Acid Controller, Acid Reducer, Acid Relief, Amazon Basic Care Acid Reducer, basic care acid reducer, and Calmicid AC — are used to relieve and prevent heartburn associated with acid indigestion and sour stomach.Prescription-strength famotidine tablets and oral suspension are indicated for active duodenal ulcers (ulcers in the small intestine), active gastric ulcers (stomach ulcers), GERD (acid reflux disease), erosive esophagitis (acid-damaged esophagus), and pathological hypersecretory conditions such as Zollinger-Ellison syndrome.
The oral suspension is also indicated in children from birth onward for GERD and, in children one year and older, for peptic ulcer disease.
Famotidine injection is used in hospitalized patients who cannot take medication by mouth.
Clinical overview from our editorial drug guide for Famotidine. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.008
Est. ASP / unit
$0.008 est.
Est. after 2% sequester
$0.008
HCPCS dosage
0.25 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J1308 = 0.25 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J1308 LEAST EXPENSIVE FIRST
16 NDCs map to J1308. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.008/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00641-6022-25 | Famotidine 10 mg/mL INJECTION | Hikma | 25 VIAL in 1 CARTON (0641-6022-25) / 2 mL... | 10 mg/mL | 2,000 | $16.00 | $0.327 | ● Active | CMS ASP |
| 25021-0753-02 | Famotidine 10 mg/mL INJECTION, SOLUTION | Sagent | 25 VIAL in 1 CARTON (25021-753-02) / 2 mL... | 10 mg/mL | 2,000 | $16.00 | $0.327 | ● Active | CMS + PDAC |
| 63323-0739-12 | Famotidine 10 mg/mL INJECTION, SOLUTION | Fresenius | 25 VIAL, SINGLE-DOSE in 1 TRAY (63323-739-... | 10 mg/mL | 2,000 | $16.00 | $0.327 | ● Active | CMS + PDAC |
| 63323-0739-16 | Famotidine 10 mg/mL INJECTION, SOLUTION | Fresenius | 25 VIAL, SINGLE-USE in 1 TRAY (63323-739-1... | 10 mg/mL | 2,000 | $16.00 | $0.327 | ● Active | CMS ASP |
| 67457-0433-22 | Famotidine 10 mg/mL INJECTION | Mylan | 25 VIAL in 1 CARTON (67457-433-22) / 2 mL... | 10 mg/mL | 2,000 | $16.00 | $0.327 | ● Active | CMS ASP |
| 70860-0751-02 | Famotidine 10 mg/mL INJECTION, SOLUTION | Athenex | 25 VIAL, SINGLE-DOSE in 1 CARTON (70860-75... | 10 mg/mL | 2,000 | $16.00 | $0.327 | Obsolete | CMS + PDAC |
| 00338-5197-41 | Famotidine 20 mg/50mL INJECTION, SOLUTION | Baxter | 12 BAG in 1 CARTON (0338-5197-41) / 50 mL... | 20 mg/50mL | 960 | $7.68 | — | ● Active | CMS + PDAC |
| 00641-6021-10 | Famotidine 10 mg/mL INJECTION | Hikma | 10 VIAL in 1 CARTON (0641-6021-10) / 20 m... | 10 mg/mL | 8,000 | $64.00 | — | ● Active | CMS ASP |
| 00641-6023-10 | Famotidine 10 mg/mL INJECTION | Hikma | 10 VIAL in 1 CARTON (0641-6023-10) / 4 mL... | 10 mg/mL | 1,600 | $12.80 | — | ● Active | CMS + PDAC |
| 51662-1375-01 | FAMOTIDINE 10 mg/mL INJECTION, SOLUTION | HF | 2 mL in 1 VIAL, SINGLE-DOSE (51662-1375-1) | 10 mg/mL | 80 | $0.64 | — | ● Active | CMS ASP |
| 51662-1375-02 | FAMOTIDINE 10 mg/mL INJECTION, SOLUTION | HF | 1 VIAL, SINGLE-DOSE in 1 POUCH (51662-1375... | 10 mg/mL | 80 | $0.64 | — | ● Active | CMS ASP |
| 63323-0738-09 | Famotidine 10 mg/mL INJECTION, SOLUTION | Fresenius | 10 VIAL, MULTI-DOSE in 1 TRAY (63323-738-0... | 10 mg/mL | 1,600 | $12.80 | — | ● Active | CMS ASP |
| 63323-0738-20 | Famotidine 10 mg/mL INJECTION, SOLUTION | Fresenius | 10 VIAL, MULTI-DOSE in 1 TRAY (63323-738-2... | 10 mg/mL | 8,000 | $64.00 | — | ● Active | CMS + PDAC |
| 67457-0448-43 | Famotidine 10 mg/mL INJECTION | Mylan | 10 VIAL in 1 CARTON (67457-448-43) / 4 mL... | 10 mg/mL | 1,600 | $12.80 | — | ● Active | CMS ASP |
| 67457-0457-20 | Famotidine 10 mg/mL INJECTION | Mylan | 10 VIAL in 1 CARTON (67457-457-20) / 20 m... | 10 mg/mL | 8,000 | $64.00 | — | ● Active | CMS ASP |
| 70860-0753-20 | Famotidine | Athenex | — | — | 8,000 | $64.00 | — | — | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$37.8K
Claims
51,954
Beneficiaries
19,055
Spend / beneficiary
$1.99
Spend / claim
$0.73
Trend by period
Where J1308 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #618 of 824
#613
NEOX NEOX RT OR CLAR... Q4148
$41.6K
#614
ADENOSINE J0153
$40.5K
#615
ATROPINE SULFATE(J04... J0462
$39.4K
#616
PHENTOLAMINE MESYLAT... J2760
$39.3K
#617
MAGNESIUM SULFATE-D5... J3475
$38.6K
#618
FAMOTIDINE J1308
$37.8K
#619
ZINPLAVA J0565
$36.7K
#620
ESANO ACA, PER SQ CM... Q4275
$36.1K
#621
DERMACYTE AMN MEM AL... Q4248
$35.9K
#622
ONDANSETRON HCL(J240... J2405
$35.4K
#623
ZIEXTENZO Q5120
$35.2K
Total claims — #50 of 824
#45
IODIXANOL(Q9966)* Q9966
56,735
#46
HEPLISAV-B 90739
54,586
#47
CIMZIA (2 PACK)* J0717
53,117
#48
LEQEMBI J0174
52,011
#49
EXPAREL J0666
51,998
#50
FAMOTIDINE J1308
51,954
#51
GAMMAGARD LIQUID J1569
49,707
#52
HYALGAN* J7321
48,959
#53
INFLIXIMAB* J1745
48,117
#54
ARANESP(J0881) J0881
47,666
#55
ONDANSETRON HCL(J240... J2405
43,411
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $37.8K | 19,055 | 51,954 | $1.99 | $0.73 |
| 2025 (Q1-Q4) | $112.6K | 38,334 | 161,893 | $2.94 | $0.70 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$114.6K
Medicare paid
$89.4K
Submitted services
14,874,813
Denial rate
11.2%
Allowed / service
$0.01
Submitted charges
$17.28M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
📊 What bills under J1308
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
16 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J1308 billing FAQ
What is HCPCS code J1308?
J1308 is a HCPCS Level II J-code used to bill Inj, famotidine, 0.25 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J1308?
One unit of J1308 represents 0.25 MG. Report the number of units equal to the dose administered divided by 0.25 MG.
How many units of J1308 should I bill?
Divide the dose administered by the code's unit size (0.25 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J1308?
The Medicare Part B payment limit is $0.008 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.008 per unit. Payment limits are revised quarterly.
Which NDCs bill under J1308?
16 NDCs currently map to J1308 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J1308 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.